Open AccessPriming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone
Author(s) -
V. Ann Stewart,
Shan McGrath,
Patrice Dubois,
Maria Grazia Pau,
Pascal Mettens,
Joseph P. Shott,
Michelle Cobb,
J. R. Burge,
David Larson,
Lisa A. Ware,
Marie-Ange Demoitié,
Gerrit Jan Weverling,
Babak Bayat,
Jerome Custers,
MarieClaude Dubois,
Joe Cohen,
Jaap Goudsmit,
D. Gray Heppner
Publication year - 2007
Publication title -
infection and immunity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.508
H-Index - 220
eISSN - 1070-6313
pISSN - 0019-9567
DOI - 10.1128/iai.01879-06
Subject(s) - circumsporozoite protein , immunogenicity , plasmodium falciparum , malaria vaccine , virology , biology , malaria , priming (agriculture) , immunology , boosting (machine learning) , immune system , botany , germination , machine learning , computer science
The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with Plasmodium falciparum malaria and also against clinical malaria and severe disease in children in areas of endemicity. Here we demonstrate with rhesus macaques that priming with a replication-defective human adenovirus serotype 35 (Ad35) vector encoding circumsporozoite protein (CS) (Ad35.CS), followed by boosting with RTS,S in an improved MPL- and QS21-based adjuvant formulation, AS01B, maintains antibody responses and dramatically increases levels of T cells producing gamma interferon and other Th1 cytokines in response to CS peptides. The increased T-cell responses induced by the combination of Ad35.CS and RTS,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more durable protection against P. falciparum infection in humans.